Successful treatment of a severe early onset case of pemphigoid gestationis with intravenous immunoglobulin in a twin pregnancy conceived with <i>in vitro</i> fertilisation in a primigravida

Calle, María de la; Vidaurrázaga, Carmen; Martínez, N. Arias; González‐Beato, M.J.; Antolín, E.; Bartha, José Luis

doi:10.1080/01443615.2016.1244809

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If PG remains refractory to treatment, or prolonged courses of steroids are required, other agents such as intravenous immunoglobulins, dapsone, and azathioprine < 2 mg/kg/day should be considered as steroid-sparing agents [65]. Intravenous immunoglobulins (FDA pregnancy category C) have a good safety profile for the patient and fetus and should be used either in monotherapy or as adjuvant treatment [66][67][68][69][70][71][72][73][74]. Dapsone (FDA pregnancy category C) is also considered safe during gestation.…”

Section: Treatmentmentioning

confidence: 99%

Pruritus in Pregnancy

et al. 2022

View full text Add to dashboard Cite

Pruritus in pregnancy is a common and burdensome symptom that may be a first sign of a pregnancy-specific pruritic disease (atopic eruption of pregnancy, polymorphic eruption of pregnancy, pemphigoid gestationis, and intrahepatic cholestasis in pregnancy) or a dermatosis coinciding with pregnancy by chance. Despite its high prevalence, pruritus is often underrated by physicians, and data regarding the safety profiles of drugs for pruritus are very limited. In this review, we illustrate the epidemiology, possible pathophysiology, clinical characteristics, and diagnostic workup of various pregnancy-related diseases and discuss antipruritic treatments. The prevalence of pruritus in pregnancy demonstrates the importance of symptom recognition and the need for an holistic approach, taking into account both the potential benefits for the patient and the potential risks to the fetus.

show abstract

Section: Treatmentmentioning

confidence: 99%

Pruritus in Pregnancy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…They found that IVIg can be useful and safe in treating pregnant patients with PV also in early phases of pregnancy. In turn, IVIg represents a good option for PG during the gestational period either as monotherapy (Nguyen et al, 2015) or combined with systemic corticosteroids (Doiron and Pratt, 2010;De la Calle et al, 2017).…”

Section: Intravenous Immunoglobulin Therapy (Fda Pregnancy Category C)mentioning

confidence: 99%

Treatment of Autoimmune Bullous Diseases During Pregnancy and Lactation: A Review Focusing on Pemphigus and Pemphigoid Gestationis

et al. 2020

View full text Add to dashboard Cite

Pregnancy may induce the onset or exacerbation of autoimmune bullous diseases such as pemphigus or pemphigoid gestationis. A shift toward T helper (Th) 2 immune response and the influence of hormonal changes have been evoked as possible triggering factors. Therapeutic management of this setting of patients may represent a challenge, mainly due to safety concerns of some immunosuppressive drugs during pregnancy and lactation. In this narrative review, we provided a comprehensive overview of the therapeutic management of autoimmune bullous diseases in pregnant and breastfeeding women, focusing on pemphigus and pemphigoid gestationis.

show abstract

Successful treatment of a severe early onset case of pemphigoid gestationis with intravenous immunoglobulin in a twin pregnancy conceived with in vitro fertilisation in a primigravida

Cited by 2 publications

References 9 publications

Pruritus in Pregnancy

Pruritus in Pregnancy

Treatment of Autoimmune Bullous Diseases During Pregnancy and Lactation: A Review Focusing on Pemphigus and Pemphigoid Gestationis

Contact Info

Product

Resources

About